WO1996010341A1 - Food and health products - Google Patents

Food and health products Download PDF

Info

Publication number
WO1996010341A1
WO1996010341A1 PCT/NL1995/000333 NL9500333W WO9610341A1 WO 1996010341 A1 WO1996010341 A1 WO 1996010341A1 NL 9500333 W NL9500333 W NL 9500333W WO 9610341 A1 WO9610341 A1 WO 9610341A1
Authority
WO
WIPO (PCT)
Prior art keywords
hypocotyls
products
substantially pure
seeds
food
Prior art date
Application number
PCT/NL1995/000333
Other languages
French (fr)
Inventor
Joseph Nicolaas Van Haaster
Original Assignee
Schouten Industries B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schouten Industries B.V. filed Critical Schouten Industries B.V.
Priority to AU36890/95A priority Critical patent/AU3689095A/en
Publication of WO1996010341A1 publication Critical patent/WO1996010341A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
    • A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae

Definitions

  • hypocotyls of Glvcine max. are a very suitable source for these plant hormones.
  • hypocotyls of Glvcine max. are a very suitable source for these plant hormones.
  • hypocotyls of Glycine max. seeds amounts to 1250 mg/100 g hypocotyls.
  • the substantially pure hypocotyls of the invention have been found to have a much higher content of isoflavones of 1636 mg/100 g hypocotyls, and also contents of 2400 to 2900 mg/100 g hypocotyls have been found in analysis.
  • the latter hypocotyls are more than 99% pure. Because of this high purity it is now practically possible to isolate sufficient quantities of glycitin to do experimental research.
  • a recommendable daily amount of isoflavones is about 50-300, preferably 75-200, more preferably about 100 mg.
  • the saponines are claimed to have curative properties against diseases of the immunosystem.
  • the substantially pure hypocotyls of the invention may form the basis of or be the active ingredient in various types of products, such as tablets, capsules, drinks, powders, candy bars, dairy products, breakfast cereals, food supplements, muscle developers, fermentation products, veterinary products, pet feed supplements, homeopathic products, bakery products, health teas, hydrolysates etc..
  • the pure hypocotyls may be subjected to a further processing step, such as toasting, steaming, roasting, milling, breaking, agglomerating, coating or combinations thereof. Processing methods that require heat lead to an inactivation of unwanted components such as trypsin inhibitor etc.. At the same time valuable flavors may develop, similar to the flavour of walnuts and other nuts. This is especially the case if the hypocotyls are roasted.
  • the intermediate fraction was freed of testae and hilums by means of an air separator.
  • the remaining fraction was further purified by means of a gravity table.
  • hypocotyls have a purity of 99%.
  • Their content of isoflavones were determined by HPLC as described by Setchell et al. (1987) . The results are shown in the following table.
  • the purified hypocotyls were roasted in hot air of 200 to 230°C.
  • the thus obtained product may be used as ingredient for breakfast cereals, candy bars, bakery products and teas.
  • the hypocotyls may be dried and pulverized to obtain a powder for use in various food and health products, homeopathic products, veterinary products, fitness products, pet feed supplements.
  • the hypocotyls may be extracted, puffed, swollen, hydrolysed and/or fermented for use in therapeutical or preventive applications.
  • a functional food product, especially intended for body-builders, in the form of a tomato juice cocktail was prepared from the following ingredients: water, tomato concentrate, extracts of walnuts, carrots, cabbage, Brussels sprouts, broccoli, garlic, orange
  • the product contained 10 mg genisteine/daidzeine as glucosides per can of 163 ml.
  • hypocotyls of Glycine max. were used as an extract as an ingredient in a drink.
  • pure hypocotyls may be used as the sole ingredient in capsules to be used as food supplements. These capsules contain 100% hypocotyls and have thus a very high content of isoflavones, tocopherols and saponines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to food or health products, comprising substantially pure hypocotyls of the seeds of Glycine max., wherein the hypocotyls are optionally further subjected to a processing step such as toasting, steaming, roasting, milling, breaking, agglomerating, coating or combinations thereof. The hypocotyls may be obtained in a substantially pure form by breaking the seeds of Glycine max., sieving the thus obtained product to obtain a first fraction, comprising larger cotyledon fragments, and a second fraction, comprising the hypocotyls, smaller cotyledon fragments and testa, removing the smaller cotyledon fragments and testa by a separation step based on the differences in floating behavior in an air flow and optionally performing a processing step thereon.

Description

FOOD AND HEALTH PRODUCTS
The present invention relates to food or health products, and to prophylactic compositions. Research into the occurrence of various forms of cancer in Western Europe and Northern America as compared to the Far East countries has led to the conclusion that the differences in daily diet may play an important role in the development of cancer. In the Western countries food products mainly originate from animal sources, whereas in Eastern countries a significantly higher amount of plant products are consumed. This led to the observation that there is a high correlation between the type of food products, especially proteins, consumed (animal versus plant) and the occurrence of breast and prostate cancer. Furthermore, it was found that urine of Japanese men contains high amounts of phyto-oestrogens (plant hormones) . The conclusion is that it appears advisable to supplement the Western diet with plant proteins and plant hormones.
It is the object of the invention to provide a source for plant hormones to be used in various products, such as food products, health products and prophylactic compositions.
It has now been found according to the invention that hypocotyls of Glvcine max. are a very suitable source for these plant hormones. However in order to avoid undesirable side-effects it is important to start with very pure hypocotyls.
The invention therefore provides hypocotyls in a substantially pure form obtainable by breaking the seeds of Glycine max.. sieving the thus obtained product to obtain a first fraction, comprising larger cotyledon fragments, and a second fraction, comprising the hypocotyls, smaller cotyledon fragments and testa, removing the smaller cotyledon fragments and testa by a separation step based on the differences in floating behavior in an air flow and optionally performing a processing step thereon.
The thus obtained hypocotyls are very pure, the purity may even be as high as 85%, preferably 90%, more preferably 95% and most preferably even 99% or higher. Due to this high degree of purity the relative amount of isoflavones in the hypocotyls of the invention is higher than reported previously. Although it is known to isolate the various active components from the hypocotyls and use these in food supplements, it was never disclosed to use the complete hypocotyl as an ingredient in food and health products. Furthermore, until the present invention it was not possible to provide hypocotyls in a very pure form. The hypocotyls contain various valuable components, such as the isoflavones diadzin, genistin and glycitin or their esters and aglucons, as well as tocopherols and saponines. Isoflavones can inhibit or prevent the onset of certain types of cancer and negatively affect the growth of tumors. Research (Hirayama, 1986) showed in a test with 143.000 women in Japan that the chance to develop breast cancer was smaller if the consumption of soya products was higher. An analogous result was obtained for prostrate cancer (Sharma et al., 1992). Furthermore it was found that the consumption of soya products significantly delayed the progression of the disease. Research by S. Barnes (unpublished results) showed that the ingredients of soya products responsible for the above effects are indeed the isoflavones. A soya protein concentrate from which the isoflavones were removed had no effect on the development of uterine cancer, whereas an unrefined concentrate had. V. Steele (unpublished results) showed that a high amount of isoflavones in the diet caused a decrease in abnormal crypts in the large intestine. Poole (1989) and Hu et al. (1991) found a protective effect. Studies in the Chinese miners community demonstrated that a higher consumption of soya products led to a decreased chance to develop lung cancer (Swanson et al. , 1992) . Animal tests, in which chemicals were used to induce tumors in liver and gall (Becker et al., 1981; Mokhtar et al., 1988) demonstrated that animals on a high isoflavone diet did not develop such disorders, whereas animals on two low-isoflavone diets did in 27% and 40% of the cases. Isoflavones are furthermore known to have a negative effect on the symptoms of the menopause, and reduces the chance to develop arteriosclerosis. They also influence the cholesterol metabolism.
The isoflavones are chemically related to oestrogens and can compete in the body for the oestrogen receptors. However, isoflavones do not induce oestrus. Genistin has less than 1% of the oestrus generating effect in mice as compared to oestrol, and daidzine has less than 10 to 20% of the activity of genistin. They compete with endogenous hormones for receptor sites but without generating the same effect.
According to the literature the isoflavone content of hypocotyls of Glycine max. seeds amounts to 1250 mg/100 g hypocotyls. The substantially pure hypocotyls of the invention have been found to have a much higher content of isoflavones of 1636 mg/100 g hypocotyls, and also contents of 2400 to 2900 mg/100 g hypocotyls have been found in analysis. The latter hypocotyls are more than 99% pure. Because of this high purity it is now practically possible to isolate sufficient quantities of glycitin to do experimental research.
A recommendable daily amount of isoflavones is about 50-300, preferably 75-200, more preferably about 100 mg.
Tocopherols are known to possess vitamin E (α- tocopherol) and anti-oxidant activity. Tocopherols exist in various forms. Hypocotyls of Glycine max. are very rich in o-, B-, τ~, and fS-tocopherol. Especially the presence of the very active 6-tocopherol in the hypocotyls of Glvcone max. is highly advantageous. The Glvcine max. tocopherols are very stable and have therefore a long shelf-life. Tocopherols are supposed to be protective against coronary heart diseases.
The saponines are claimed to have curative properties against diseases of the immunosystem.
The substantially pure hypocotyls of the invention may form the basis of or be the active ingredient in various types of products, such as tablets, capsules, drinks, powders, candy bars, dairy products, breakfast cereals, food supplements, muscle developers, fermentation products, veterinary products, pet feed supplements, homeopathic products, bakery products, health teas, hydrolysates etc..
The pure hypocotyls may be subjected to a further processing step, such as toasting, steaming, roasting, milling, breaking, agglomerating, coating or combinations thereof. Processing methods that require heat lead to an inactivation of unwanted components such as trypsin inhibitor etc.. At the same time valuable flavors may develop, similar to the flavour of walnuts and other nuts. This is especially the case if the hypocotyls are roasted.
The hypocotyls may also be used for isolating the isoflavones and/or tocopherols and/or saponines therefrom. Both the hypocotyls and isolated components thereof may be used in prophylactic, therapeutical and homeopathic compositions.
The present invention will be further elucidated in the following examples which are given for illustration purposes only and are not intended to limit the scope of the invention. EXAMPLES
EXAMPLE 1
Preparation of hypocotyls according to the invention Seeds of Glvcine max. were sifted on a sieving machine having screens with a sieve width of 6 mm to remove unwanted components. The purified seeds were then broken by a crushing roller to obtain 2 to 20 pieces per seed. The broken seeds were sifted on a sieving machine with screens having apertures of 1 to 2 mm diameter.
The intermediate fraction was freed of testae and hilums by means of an air separator. The remaining fraction was further purified by means of a gravity table.
The thus obtained hypocotyls have a purity of 99%. Their content of isoflavones were determined by HPLC as described by Setchell et al. (1987) . The results are shown in the following table.
Isoflavone Concentration
Daidzin 13.11 mg/ml
Genistin 2.47 mg/g
Daidzein 0.71 mg/g
Genistein 0.07 mg/g
Total 16.36 mg/g
The purified hypocotyls were roasted in hot air of 200 to 230°C. The thus obtained product may be used as ingredient for breakfast cereals, candy bars, bakery products and teas. As an alternative the hypocotyls may be dried and pulverized to obtain a powder for use in various food and health products, homeopathic products, veterinary products, fitness products, pet feed supplements. As a further alternative the hypocotyls may be extracted, puffed, swollen, hydrolysed and/or fermented for use in therapeutical or preventive applications.
EXAMPLE 2 Tomato uice cocktail
A functional food product, especially intended for body-builders, in the form of a tomato juice cocktail was prepared from the following ingredients: water, tomato concentrate, extracts of walnuts, carrots, cabbage, Brussels sprouts, broccoli, garlic, orange
(oil) , salmon (oil) , green tea, rice, cherries, licorice and soy lecithin, natural flavors, natural β-carotene, natural vitamin E and 0.6% of an extract of the hypocotyls of Glvcine max.. The product contained 10 mg genisteine/daidzeine as glucosides per can of 163 ml.
EXAMPLE 3
Capsules containing the hypocotyls
In the previous example the hypocotyls of Glycine max. were used as an extract as an ingredient in a drink. As an alternative the pure hypocotyls may be used as the sole ingredient in capsules to be used as food supplements. These capsules contain 100% hypocotyls and have thus a very high content of isoflavones, tocopherols and saponines.
REFERENCES
Hirayama, T. , "A Large Scale Cofort Study on Cancer Risks by Diet - With Special Reference to the Risk Reducing Effects of Green-Yellow Vegetable Consumption". In: "Diet, Nutrition and Cancer", Y Ayashi et al. (eds.) Utrecht, The Netherlands: Tokyo?VNU Sci Press, 1986, p.41-53
Shar a, O.P. et al., "Soy of Dietary Source Plays a
Preventive Role against the Pathogenesis of Prostatitis in Rats." Journ. of Steroid Biochem. Mol. Biol. 43, 557- 564 (1992).
Poole, C. , "A Case-Control Study of Diet and Colon Cancer (Dissertation) , Boston, MA: HArvard School of Medical Health (1989).
Hu, J. et al., "Diet and Cancer of the Colon and Rectum: A Case-Control Study in China". Int. J. Epidemiol. 20, 362-367 (1991) .
Swanson, C.A. et al., "Dietary Determinants of Lung- Cancer Risk: Results from a Case-Control Study in Yunnan Province, China". Int. J. Cancer 50, 876-880 (1992).
Becker, F.F., "Inhibition of Spontaneous Hepato- carcinogenesis in C3H/He Mice by Edi Pro A, an Isolated Soy Protein", Carcinogenesis 2, 1213-1214 (1981).
Mokhtar, N.M. et al., "Effect of Soybean Feeding on Exeprimental Carcinogenesis-III. Carcinogenecity of Nitrite and Dibutylamine in Mice: A Histopathological Study". Eur. J. Clin. Oncol. 24, 403-411 (1988).
Setchell, K.D.R. et al., J. Chromatography 368, 315-323 (1987) .

Claims

1. Food or health product, comprising substan¬ tially pure hypocotyls of the seeds of Glvcine max..
2. Food or health product as claimed in claim
1, wherein the hypocotyls are further subjected to a processing step such as toasting, steaming, roasting, milling, breaking, agglomerating, coating or combinations thereof.
3. Food or health product as claimed in claim 1 or 2, wherein the hypocotyls are obtainable in a substan¬ tially pure form by breaking the seeds of Glycine max.. sieving the thus obtained product to obtain a first fraction, comprising larger cotyledon fragments, and a second fraction, comprising the hypocotyls, smaller coty¬ ledon fragments and testa, removing the smaller cotyledon fragments and testa by a separation step based on the differences in floating behavior in an air flow and optionally performing a processing step thereon.
4. Food or health product as claimed in claim 1 to 3, wherein the product is in a form selected from the group consisting of tablets, capsules, drinks, powders, candy bars, dairy products, breakfast cereals, food supplements, muscle developers, fermentation products, veterinary products, pet feed supplements, homeopathic products, bakery products, health teas, hydrolysates.
5. Substantially pure hypocotyls of the seeds of Glycine max. obtainable by breaking the seeds, sieving the thus obtained product to obtain a first fraction, comprising larger cotyledon fragments, and a second fraction, comprising the hypocotyls, smaller cotyledon fragments and testa, removing the smaller cotyledon fragments and testa by a separation step based on the differences in floating behavior in an air flow and optionally performing a processing step thereon.
6. Substantially pure hypocotyls as claimed in claim 5 for use in food products.
7. Substantially pure hypocotyls as claimed in claim 5 for use in health products.
8. Substantially pure hypocotyls as claimed in claim 5 for use in prophylactic compositions.
9. Substantially pure hypocotyls as claimed in claim 5 for use in homeopathic products.
10. Substantially pure hypocotyls as claimed in claim 5 for use as a raw material for the isolation of isoflavones, such as daidzin, genistin and glycitin.
11. Substantially pure hypocotyls as claimed in claim 5 for use as a raw material for the isolation of tocopherols and/or saponines.
12. Use of pure hypocotyls as claimed in claim 5 for the preparation of prophylactic compositions.
13. Prophylactic composition comprising as an active ingredient substantially pure hypocotyls of the seeds of Glycine max.. and a suitable excipient.
14. Method for manufacturing substantially pure hypocotyls of the seeds of Glvcine max.. comprising the steps of breaking the seeds, sieving the thus obtained product to obtain a first fraction, comprising larger cotyledon fragments, and a second fraction, comprising the hypocotyls, smaller cotyledon fragments and testa, removing the smaller cotyledon fragments and testa by a separation step based on the differences in floating behavior in an air flow and optionally performing a processing step thereon.
PCT/NL1995/000333 1994-10-03 1995-10-03 Food and health products WO1996010341A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36890/95A AU3689095A (en) 1994-10-03 1995-10-03 Food and health products

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL9401618 1994-10-03
NL9401618 1994-10-03
US50980395A 1995-08-01 1995-08-01
US08/509,803 1995-08-01

Publications (1)

Publication Number Publication Date
WO1996010341A1 true WO1996010341A1 (en) 1996-04-11

Family

ID=26647263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1995/000333 WO1996010341A1 (en) 1994-10-03 1995-10-03 Food and health products

Country Status (2)

Country Link
AU (1) AU3689095A (en)
WO (1) WO1996010341A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656786A4 (en) * 1992-05-19 1997-06-11 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof.
WO1998003084A1 (en) * 1996-07-18 1998-01-29 Nutricor, Inc. Nutritious food preparations and methods for making them
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
EP0857428A2 (en) * 1997-02-06 1998-08-12 Kikkoman Corporation Dietetic soy based products and method for production thereof
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
DE19732866A1 (en) * 1997-07-30 1999-02-18 Indena Spa Soya extract containing group B soya saponin(s)
DE19732855A1 (en) * 1997-07-30 1999-02-18 Indena Spa Soya extract containing group B soya saponin(s)
US6015785A (en) * 1996-04-12 2000-01-18 Protein Technologies International, Inc. Aglucone isofavone enriched vegetable protein extract and isolate and process for producing
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
US6509043B1 (en) 1998-11-25 2003-01-21 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
EP1331857A1 (en) * 2000-11-09 2003-08-06 Cargill, Incorporated Soybean processing
US6607757B2 (en) 1997-07-30 2003-08-19 Indena S.P.A. Soya extract, process for its preparation and pharmaceutical composition
US6630178B1 (en) 1998-11-25 2003-10-07 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6664382B2 (en) 1996-06-11 2003-12-16 Solae, Llc Recovery of isoflavones from soy molasses
US6787151B2 (en) 2001-08-10 2004-09-07 Lipton, Division Of Conopco, Inc. Composition for lowering blood cholesterol
US6855359B2 (en) 2002-11-15 2005-02-15 Cargill, Incorporated Soluble isoflavone compositions
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
WO2006076240A2 (en) * 2005-01-10 2006-07-20 The Procter & Gamble Company Compositions, products and methods for controlling weight in a mammal
AU2004224982B2 (en) * 1996-08-30 2007-09-13 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8362317B2 (en) 2007-03-09 2013-01-29 Monsanto Technology Llc Preparation and use of plant embryo explants for transformation
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
JP2015221014A (en) * 2014-05-23 2015-12-10 不二製油グループ本社株式会社 Soybean hypocotyl processed product
US9648814B2 (en) 2003-08-05 2017-05-16 Monsanto Technology Llc Method and apparatus for substantially isolating plant tissues
WO2019148250A1 (en) * 2018-02-02 2019-08-08 Commonwealth Scientific And Industrial Research Organisation Protecting a bioactive and/or precursor thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130593A (en) * 1984-07-20 1986-02-12 Pelican:Kk Method of extracting saponin component from soybeam hypocotyl
JPH05271087A (en) * 1992-03-24 1993-10-19 Marusan I Kk Method for processing soybean hypocotyl, processed soybean hypocotyl and its utilization
WO1993023069A1 (en) * 1992-05-19 1993-11-25 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130593A (en) * 1984-07-20 1986-02-12 Pelican:Kk Method of extracting saponin component from soybeam hypocotyl
JPH05271087A (en) * 1992-03-24 1993-10-19 Marusan I Kk Method for processing soybean hypocotyl, processed soybean hypocotyl and its utilization
WO1993023069A1 (en) * 1992-05-19 1993-11-25 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8613, Derwent World Patents Index; Class D13, AN 86-084456 *
DATABASE WPI Section Ch Week 9346, Derwent World Patents Index; Class B04, AN 93-365153 *

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656786A4 (en) * 1992-05-19 1997-06-11 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof.
EP1477178A3 (en) * 1992-05-19 2005-02-16 KELLY, Graham Edmund Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6015785A (en) * 1996-04-12 2000-01-18 Protein Technologies International, Inc. Aglucone isofavone enriched vegetable protein extract and isolate and process for producing
US6706292B2 (en) 1996-06-11 2004-03-16 Solae, Llc Recovery of isoflavones from soy molasses
US6680381B1 (en) 1996-06-11 2004-01-20 Solae, Llc Recovery of isoflavones from soy molasses
US6664382B2 (en) 1996-06-11 2003-12-16 Solae, Llc Recovery of isoflavones from soy molasses
WO1998003084A1 (en) * 1996-07-18 1998-01-29 Nutricor, Inc. Nutritious food preparations and methods for making them
GB2331015B (en) * 1996-08-30 2001-05-09 Novogen Res Pty Ltd Therapeutic methods and compositions involving isoflavones
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US6649648B1 (en) 1996-08-30 2003-11-18 Novogen Research Pty Limited Therapeutic methods and compositions involving isoflavones
AU2004224982B2 (en) * 1996-08-30 2007-09-13 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
GB2331015A (en) * 1996-08-30 1999-05-12 Novogen Res Pty Ltd Therapeutic methods and compositions involving isoflavones
EP1927352A2 (en) * 1996-08-30 2008-06-04 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
EP1927352A3 (en) * 1996-08-30 2008-11-19 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US6051234A (en) * 1997-02-06 2000-04-18 Kikkoman Corporation Health diet for preventing diseases caused by life-habit
EP0857428A2 (en) * 1997-02-06 1998-08-12 Kikkoman Corporation Dietetic soy based products and method for production thereof
EP0857428A3 (en) * 1997-02-06 1999-07-28 Kikkoman Corporation Dietetic soy based products and method for production thereof
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
DE19732855A1 (en) * 1997-07-30 1999-02-18 Indena Spa Soya extract containing group B soya saponin(s)
US7108871B2 (en) 1997-07-30 2006-09-19 Indena S.P.A. Methods of treatment using a soya extract
DE19732866A1 (en) * 1997-07-30 1999-02-18 Indena Spa Soya extract containing group B soya saponin(s)
DE19732855C2 (en) * 1997-07-30 1999-11-11 Indena Spa Special soy extract, its preparation, formulations containing it and their use for the prevention or treatment of cancer
US6607757B2 (en) 1997-07-30 2003-08-19 Indena S.P.A. Soya extract, process for its preparation and pharmaceutical composition
DE19732866C2 (en) * 1997-07-30 1999-11-04 Indena Spa New soy extracts, their preparation, formulations based on them and their use for the prevention or treatment of pre-menopausal and post-menopausal symptoms
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
US6630178B1 (en) 1998-11-25 2003-10-07 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6509043B1 (en) 1998-11-25 2003-01-21 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
US6572876B2 (en) 1999-04-23 2003-06-03 Solae, Llc Administering a composition containing plant sterol, soy protein and isoflavone for reducing LDL-cholesterol
US6669952B2 (en) 1999-04-23 2003-12-30 Solae, Llc Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US6579534B2 (en) 1999-04-23 2003-06-17 Solae, Llc Composition containing soy hypocotyl material and plant sterol for reducing LDL-cholesterol
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
EP1331857A4 (en) * 2000-11-09 2005-03-02 Cargill Inc Soybean processing
US7045164B2 (en) 2000-11-09 2006-05-16 Cargill, Incorporated Soybean processing
EP1331857A1 (en) * 2000-11-09 2003-08-06 Cargill, Incorporated Soybean processing
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US6787151B2 (en) 2001-08-10 2004-09-07 Lipton, Division Of Conopco, Inc. Composition for lowering blood cholesterol
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9408824B2 (en) 2002-07-24 2016-08-09 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8450364B2 (en) 2002-10-29 2013-05-28 Brigham Young University Use of equol for treating androgen mediated diseases
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US9408825B2 (en) 2002-10-29 2016-08-09 Brigham Young University Use of equol for treating androgen mediated diseases
US6855359B2 (en) 2002-11-15 2005-02-15 Cargill, Incorporated Soluble isoflavone compositions
US11212972B2 (en) 2003-08-05 2022-01-04 Monsanto Technology Llc Method and apparatus for substantially isolating plant tissues
US10433503B2 (en) 2003-08-05 2019-10-08 Monsanto Technology Llc Method and apparatus for substantially isolating plant tissues
US9648814B2 (en) 2003-08-05 2017-05-16 Monsanto Technology Llc Method and apparatus for substantially isolating plant tissues
WO2006076240A2 (en) * 2005-01-10 2006-07-20 The Procter & Gamble Company Compositions, products and methods for controlling weight in a mammal
WO2006076240A3 (en) * 2005-01-10 2006-10-19 Procter & Gamble Compositions, products and methods for controlling weight in a mammal
US9790512B2 (en) 2007-03-09 2017-10-17 Monsanto Technology Llc Preparation and use of plant embryo explants for transformation
US9885053B2 (en) 2007-03-09 2018-02-06 Monsanto Technology Llc Method of meristem excision and transformation
US9006513B2 (en) 2007-03-09 2015-04-14 Monsanto Technology Llc Preparation and use of plant embryo explants for transformation
US8937216B2 (en) 2007-03-09 2015-01-20 Monsanto Technology Llc Method of meristem excision and transformation
US10584345B2 (en) 2007-03-09 2020-03-10 Monsanto Technology Llc Preparation and use of plant embryo explants for transformation
US10717983B2 (en) 2007-03-09 2020-07-21 Monsanto Technology Llc Method of meristem excision and transformation
US10920235B2 (en) 2007-03-09 2021-02-16 Monsanto Technology Llc Apparatus for the preparation and use of plant embryo explants for transformation
US8362317B2 (en) 2007-03-09 2013-01-29 Monsanto Technology Llc Preparation and use of plant embryo explants for transformation
US11485980B2 (en) 2007-03-09 2022-11-01 Monsanto Technology, Llc Method of meristem excision and transformation
US11542514B2 (en) 2007-03-09 2023-01-03 Monsanto Technology, Llc Apparatus for the preparation and use of plant embryo explants for transformation
US11566252B2 (en) 2007-03-09 2023-01-31 Monsanto Technology, Llc Preparation and use of plant embryo explants for transformation
JP2015221014A (en) * 2014-05-23 2015-12-10 不二製油グループ本社株式会社 Soybean hypocotyl processed product
WO2019148250A1 (en) * 2018-02-02 2019-08-08 Commonwealth Scientific And Industrial Research Organisation Protecting a bioactive and/or precursor thereof

Also Published As

Publication number Publication date
AU3689095A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
WO1996010341A1 (en) Food and health products
Bonku et al. Health aspects of peanuts as an outcome of its chemical composition
Hernández-Ledesma Quinoa (Chenopodium quinoa Willd.) as source of bioactive compounds: A review
Pihlanto et al. Bioactivities of alternative protein sources and their potential health benefits
Barnes The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products
Graf et al. Innovations in health value and functional food development of quinoa (Chenopodium quinoa Willd.)
Campos-Vega et al. Minor components of pulses and their potential impact on human health
EP0656786B2 (en) Use of isoflavone phyto-oestrogen extracts of soy or clover
TW491688B (en) Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
Hassan Soybean, nutrition and health
US20040219235A1 (en) Custom made herbal health promotive formulation for females/expectant mothers
Soni et al. Flaxseed—Composition and its health benefits
WO1998003084A1 (en) Nutritious food preparations and methods for making them
JP4684556B2 (en) Method for producing SDG and its blended food and drink
Niazi et al. Date palm: composition, health claim and food applications
Salgado et al. Soy as a functional food
Naresh et al. Engineered soybean-based beverages and their impact on human health
Singh et al. Pumpkin seeds as nutraceutical and functional food ingredient for future: A review
JP2005500074A (en) Nutritional supplements derived from herbs for women / pregnant women and methods for preparing the same
Vineet Kumar et al. Nutritional value of soybean.
Vohra et al. An insight of pulses: From food to cancer treatment
Mannen et al. Changes in plasma concentration of flavonoids after ingestion of a flavonoid-rich meal prepared with basic foodstuffs
WO2005105125A1 (en) Preventive or remedy for osteroporosis
Khatib et al. Fig, carob, pistachio, and health
Ojwang Anti-inflammatory properties of cowpea phenotypes with different phenolic profiles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA